Mechanistically, the data suggest that our antibodies promote T cell conjugation with tumor cells and APCs including monocytes through antibody-antigen binding and Fc-FcγR binding, and inhibit immune checkpoints, potentiating T cell activation and cancer cell killing (Fig. 7). Here, FCGR2A is linked to cancer.